<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491256</url>
  </required_header>
  <id_info>
    <org_study_id>RESIST-ACS</org_study_id>
    <nct_id>NCT01491256</nct_id>
  </id_info>
  <brief_title>Index of Microcirculatory Resistance After Drug-Eluting Stent Implantation With High Dose Atorvastatin Loading</brief_title>
  <acronym>RESIST-ACS</acronym>
  <official_title>Randomized Comparison Multicenter Trial of High Dose Atorvastatin Pre-treatment on Microcirculatory Dysfunction After Drug-ElutIng Stent Implantation in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Korean Society of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Korean Society of Circulation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-treatment with statins decreased the incidence of cardiac enzyme increase after
      percutaneous coronary intervention (PCI) and distal embolization suspected to cause post-PCI
      myocardial damage. This study evaluates the effect of high dose atorvastatin pre-treatment on
      post-procedural index of microcirculatory resistance (IMR) values that are introduced for
      assessing the status of the microcirculation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred patients with non-ST elevation acute coronary syndrome will be randomly assigned
      to either high dose atorvastatin pre-treatment group(80 mg loading within 24 hours plus 40mg
      busting within 2 hours before PCI) or control group(atorvastatin 10mg administration within
      24 hours before PCI). An intracoronary pressure/temperature sensor-tipped guidewire is used.
      Thermodilution curves are obtained during maximal hyperemia. The IMR was calculated from the
      ratio of the mean distal coronary pressure at maximal hyperemia to the inverse of mean
      hyperemic transit time. Creatine kinase-myocardial band(CK-MB) and CRP level will be measured
      at baseline and at 12~24 hours after PCI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of microcirculatory resistance (IMR)</measure>
    <time_frame>Immediately after percutaneous coronary intervention</time_frame>
    <description>After stent implantation and adjunctive balloon dilatation, final angiogram will be taken. If the final angiogram shows successful results, IMR will be measured and the procedure will be finished.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events (death, myocardial infarction, target vessel failure</measure>
    <time_frame>1 year after index procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>High dose Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm of pre-procedural high dose atorvastatin loading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No pre-procedural high dose atorvastatin loading</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-procedural High dose atorvastatin loading</intervention_name>
    <description>Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention</description>
    <arm_group_label>High dose Atorvastatin</arm_group_label>
    <other_name>Lipitor (Pfizer)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No pre-procedural high-dose atorvastatin loading</intervention_name>
    <description>atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Lipitor (Pfizer)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of Non-ST elevation acute coronary syndrome planed to elective percutaneous
             coronary intervention

        Exclusion Criteria:

          -  ST elevation myocardial infarction

          -  Cardiogenic shock

          -  Congestive heart failure with pulmonary edema

          -  Severe left ventricular dysfunction (LVEF &lt; 30%)

          -  History of previous coronary revascularization therapy

          -  chronic total coronary occlusion

          -  3 vessel disease

          -  Target lesion at distal segments or branches

          -  Ostial lesion

          -  Excessive coronary calcification or thrombi

          -  Elevated transaminase

          -  Renal dysfunction (serum creatinine &gt; 2.0mg/dL

          -  History of myopathy

          -  Contra-indication to anti-platelet therapy

          -  Not indicated for percutaneous coronary intervention

          -  Other co-morbidity with life expectancy less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong-Ki Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KangWon National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bong-Ki Lee, MD, PhD</last_name>
    <phone>+82-10-6373-9290</phone>
    <email>nicedr@nate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <zip>200-722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Ki Lee, MD, PhD</last_name>
      <phone>+82-10-6373-9290</phone>
      <email>nicedr@nate.com</email>
    </contact>
    <investigator>
      <last_name>Bon-Kwon Koo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chang-WooK Nam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Woon Rha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joon-Hyung Doh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Woo-Young Chung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Jae Tahk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin-Bae Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ki-Dong Yoo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>December 11, 2011</last_update_submitted>
  <last_update_submitted_qc>December 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Korean Society of Circulation</investigator_affiliation>
    <investigator_full_name>Bong-Ki Lee</investigator_full_name>
    <investigator_title>Assistance Professor of Medicine, Kangwon National University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Index of microcirculatory resistance</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>drug-eluting stent</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 1, 2015</submitted>
    <returned>April 13, 2015</returned>
    <submitted>August 19, 2017</submitted>
    <returned>February 23, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

